These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7106168)

  • 1. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.
    Birkett DJ; Miners JO; Attwood J
    Br J Clin Pharmacol; 1983 May; 15(5):567-9. PubMed ID: 6860533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C; Schlicht F; Walter E; Gundert-Remy U; Hildebrandt R; de Vries J; Wang NS; Harenberg J; Weber E
    Eur J Clin Pharmacol; 1983; 25(6):797-801. PubMed ID: 6141054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal clearance of sulphinpyrazone in man.
    Lentjes EG; Russel FG; van Ginneken CA
    Eur J Clin Pharmacol; 1986; 31(4):473-8. PubMed ID: 3816927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of sulphinpyrazone with warfarin.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):327-31. PubMed ID: 7106169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1982 Feb; 13(2):177-85. PubMed ID: 7059415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
    Schlicht F; Staiger C; de Vries J; Gundert-Remy U; Hildebrandt R; Harenberg J; Wang NS; Weber E
    Eur J Clin Pharmacol; 1985; 28(1):97-103. PubMed ID: 3987792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide.
    Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1977 Mar; 21(3):301-9. PubMed ID: 837649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verapamil disposition--effects of sulphinpyrazone and cimetidine.
    Wing LM; Miners JO; Lillywhite KJ
    Br J Clin Pharmacol; 1985 Mar; 19(3):385-91. PubMed ID: 3986090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.
    Wing LM; Miners JO
    Br J Clin Pharmacol; 1985 Nov; 20(5):482-5. PubMed ID: 3878154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of anticoagulant response to warfarin by sulphinpyrazone: a double-blind study in patients with prosthetic heart valves.
    Girolami A; Fabris F; Casonato A; Randi ML
    Clin Lab Haematol; 1982; 4(1):23-6. PubMed ID: 7067372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.
    Miners JO; Wing LM; Lillywhite KJ; Smith KJ
    Br J Clin Pharmacol; 1984 Dec; 18(6):853-60. PubMed ID: 6152176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of drug-drug interactions in sheep: tolbutamide and sulfadimethoxine.
    Thiessen JJ; Rowland M
    J Pharm Sci; 1977 Aug; 66(8):1063-70. PubMed ID: 894490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
    Pay GF; Wallis RB; Zelaschi D
    Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphinpyrazone metabolism during long-term therapy.
    Pedersen AK; Jakobsen P
    Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic analysis of the interaction between dicoumarol and tolbutamide in man.
    Jähnchen E; Meinertz T; Gilfrich HJ; Groth U
    Eur J Clin Pharmacol; 1976 Sep; 10(5):349-56. PubMed ID: 61862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
    Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
    Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of different oral anticoagulants on diphenylhydantoin (DPH) and tolbutamide metabolism.
    Skovsted L; Kristensen M; Hansen M; Siersbaek-Nielsen K
    Acta Med Scand; 1976; 199(6):513-5. PubMed ID: 59517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphinpyrazone and warfarin: a probable drug interaction.
    Gallus A; Birkett D
    Lancet; 1980 Mar; 1(8167):535-6. PubMed ID: 6102248
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.
    Zilly W; Breimer DD; Richter E
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):219-27. PubMed ID: 1233266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.